Stock-Based Compensation | 5. Stock-Based Compensation The compensation costs that have been charged against income for the thirteen weeks ended April 30, 2016 and May 2, 2015 were as follows (in thousands): Thirteen Weeks Ended April 30, 2016 May 2, 2015 Stock-based compensation expense by type: Stock options $ 381 $ 340 Restricted stock unit awards, including performance-based 1,709 2,278 Employee stock purchases 36 37 Director deferred compensation 23 18 Total stock-based compensation expense 2,149 2,673 Income tax benefit recognized 781 985 Stock-based compensation expense, net of income tax $ 1,368 $ 1,688 In the thirteen weeks ended April 30, 2016 and May 2, 2015, we granted the following equity awards: Thirteen Weeks Ended April 30, 2016 May 2, 2015 Stock options 36,041 19,090 Restricted stock unit awards 100,775 69,529 Performance-based restricted stock unit awards 45,300 29,300 Deferred stock units 13,482 11,252 At April 30, 2016, the total compensation costs, related to nonvested restricted stock unit awards not yet recognized was $10.9 million and the weighted-average period over which such awards are expected to be recognized was 2.8 years. There are no future compensation costs related to nonvested stock options to be recognized at April 30, 2016. Under the 2012 Non-Employee Director Equity Plan (2012 Plan), a total of 2,851 and 1,981 shares of our common stock were awarded during the thirteen weeks ended April 30, 2016 and May 2, 2015, respectively, as part of the annual equity award to directors in the first quarter. The weighted-average grant date fair value of stock options granted during the thirteen weeks ended April 30, 2016 and May 2, 2015 was $10.56 and $17.82 per share, respectively. Our employee purchases of common stock, the average price per share and the weighted-average grant date fair value of shares purchased through the our employee stock purchase plan were as follow: Thirteen Weeks Ended April 30, 2016 May 2, 2015 Shares purchased 5,617 3,449 Average price per share $ 25.70 $ 41.17 Weighted average fair value at grant date $ 6.47 $ 10.72 |